Watson Unithroid promotions
Executive Summary
Watson is mailing marketing literature to managed care organizations as part of a new promotional campaign for Unithroid (levothyroxine). FDA's call for Abbott to reduce Synthroid production gradually until the drug is approved prompted increased Watson focus on the managed care sector (1"The Pink Sheet" July 16, p. 16). The company particularly hopes to attract mid-sized organizations who are most likely to be impacted by the Synthroid phase-out
You may also be interested in...
FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials